Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
Journal for ImmunoTherapy of Cancer · 2023
DOI: 10.1136/jitc-2022-006629 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Prachi Bhave und 19 weiteren Autor:innen. Beteiligte Einrichtung: Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia. Hauptthemen laut MEDLINE: Quality of Life, Melanoma. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
In patients with stage III melanoma, despite surgical resection and adjuvant systemic therapy, locoregional recurrences still occur. The randomized, phase III Trans-Tasman Radiation Oncology Group (TROG) 02.01 trial demonstrated that adjuvant radiotherapy (RT) after complete lymphadenectomy (CLND) halves the incidence of melanoma recurrence within local nodal basins without improving overall survival or quality of life. However, the study was conducted prior to the current era of adjuvant systemic therapies and when CLND was the standard approach for microscopic nodal disease. As such, there is currently no data on the role of adjuvant RT in patients with melanoma who recur during or after adjuvant immunotherapy, including those that may or may not have undergone prior CLND. In this study, we aimed to answer this question.
Methods
Patients with resected stage III melanoma who received adjuvant anti-programmed cell death protein-1 (PD-1) (±ipilimumab) immunotherapy with a subsequent locoregional (lymph node and/or in-transit metastases) recurrence were retrospectively identified. Multivariable logistic and Cox regression analyses were conducted. Primary outcome was rate of subsequent locoregional recurrence; secondary outcomes were locoregional recurrence-free survival (lr-RFS2) and overall RFS (RFS2) to second recurrence.
Results
In total, 71 patients were identified: 42 (59%) men, 30 (42%) BRAF V600E mutant, 43 (61%) stage IIIC at diagnosis. Median time to first recurrence was 7 months (1–44), 24 (34%) received adjuvant RT and 47 (66%) did not. Thirty-three patients (46%) developed a second recurrence at a median of 5 months (1–22). The rate of locoregional relapse at second recurrence was lower in those who received adjuvant RT (8%, 2/24) compared with those who did not (36%, 17/47, p=0.01). Adjuvant RT at first recurrence was associated with an improved lr-RFS2 (HR 0.16, p=0.015), with a trend towards an improved RFS2 (HR 0.54, p = 0.072) and no effect on risk of distant recurrence or overall survival.
Conclusion
This is the first study to investigate the role of adjuvant RT in patients with melanoma with locoregional disease recurrence during or after adjuvant anti-PD-1-based immunotherapy. Adjuvant RT was associated with improved lr-RFS2, but not risk of distant recurrence, demonstrating a likely benefit in locoregional disease control in the modern era. Further prospective studies are required to validate these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.
- Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
- Melanoma Institute Australia, Sydney, New South Wales, Australia.
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
- Department of Dermatology, University Hospital Zürich, Zurich, Switzerland.
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
ORCID-Profile: Prachi Bhave, Serigne N Lo, Zeynep Eroglu
Zitieren
APA
Bhave, P., Hong, A., Lo, S. N., Johnson, R., Mangana, J., Johnson, D. B., Dulgar, O., Eroglu, Z., Yeoh, H. L., Haydon, A., Lodde, G. C., Livingstone, E., Khattak, A., Kähler, K., Hausschild, A., McArthur, G. A., Menzies, A. M., Long, G., Wang, W., & Carlino, M. S. (2023). Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-006629
Vancouver
Bhave P, Hong A, Lo SN, Johnson R, Mangana J, Johnson DB, et al. Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2022-006629
BibTeX
@article{Bhave2023,
author = {Bhave, Prachi and Hong, Angela and Lo, Serigne N and Johnson, Rebecca and Mangana, Johanna and Johnson, Douglas B and Dulgar, Ozgecan and Eroglu, Zeynep and Yeoh, Hui-Ling and Haydon, Andrew and Lodde, Georg C and Livingstone, Elisabeth and Khattak, Adnan and Kähler, Katharina and Hausschild, Axel and McArthur, Grant A and Menzies, Alexander Maxwell and Long, Georgina and Wang, Wei and Carlino, Matteo S},
title = {Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
doi = {10.1136/jitc-2022-006629}
}
EUVIMED